Winslow Evans & Crocker’s Intellia Therapeutics NTLA Stock Holding History

Winslow Evans & Crocker’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	$76K	Hold	1,392	–	–	0.01%	506
2020 Q3	$28K	Hold	1,392	–	–	0.01%	564
2020 Q2	$29K	Hold	1,392	–	–	0.01%	546
2020 Q1	$18K	Buy	+1,392	New	+$18.8K	0.01%	595
2018 Q4	–	Sell	-2,000	Closed	-$58K	–	1123
2018 Q3	$58K	Hold	2,000	–	–	0.02%	456
2018 Q2	$56K	Hold	2,000	–	–	0.02%	470
2018 Q1	$42.2K	Buy	+2,000	New	+$49.2K	0.01%	516

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return

AVAI

Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return

AVAX

Atlas Venture Associates XI Cambridge, Massachusetts $631M AUM

Winslow Evans & Crocker's NTLA Position: Q4 2020 in Review

Winslow Evans & Crocker held its Intellia Therapeutics (NTLA) position steady in Q4 2020 at 1,392 shares worth $76K. The position accounts for 0.01% of the portfolio, ranked #506.

Winslow Evans & Crocker first reported a position in NTLA in Q1 2018 and has held it in 7 quarters since. 240 funds tracked by Wall St. Rank hold NTLA as of Q4 2020.

Winslow Evans & Crocker held 1,392 shares of Intellia Therapeutics worth $76K as of Q4 2020.
Winslow Evans & Crocker left its Intellia Therapeutics share count unchanged in Q4 2020.
Intellia Therapeutics made up 0.01% of Winslow Evans & Crocker's portfolio in Q4 2020, its #506 holding.
Winslow Evans & Crocker first reported a position in Intellia Therapeutics in Q1 2018 and has held it in 7 quarters since.
240 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2020.

Based on Winslow Evans & Crocker's 13F filing for Q4 2020, filed 3 Feb 2021.